HealthResJ, health, medicine, nursing, research

Epidemiological - clinical features of primary malignant brain tumors of patients who underwent surgical resection and / or radiotherapy

Published: Οκτ 1, 2015
Brain tumors histological classification Ki-67 radiotherapy chemotherapy
Anthoula Lagiou
Ioannis Papagiannopoulos
Nikoletta Margari
Georgios Vasilopoulos

The aim of the present study was to describe the demographic characteristics of patients diagnosed with primary brain tumor, the clinical features and prognostic indicators of disease progression and treatment they received.
Methods: A retrospective descriptive study was conducted on a convenience sample of 47 patients who attended the radiotherapeutic department of General Hospital of Athens over three years, from May 2011 until May 2014.
For analysis used the statistical program SPSS 18.0.
Results: 59.6% of patients were male and 40.4% of patients were between 61 and 69 years. 85.1% of patients had glioblastomamultiforme and meningioma 8.5%. 57.5% of patients with glioblastomamultiforme were men and 50.0% of patients with meningioma. It was found that the patients with grade I-III were considerably higher percentage between 61 and 69 years as compared to patients with grade IV (p = 0,021). Patients with grade IV underwent chemotherapy significantly higher rate compared with patients with grade I-III. No significant difference was found in the course of radiotherapy among patients with grade IV and patients with grade I-III. Differed significantly Ki-67 among patients with grade IV and of patients with grade I-III patients with grade IV were higher Ki-67.
Conclusion: Glioblastoma multiforme (GBM) is the most frequently diagnosed intracranial malignant tumor in adults. Typical treatment for glioblastomas, with surgical resection followed by radiation and chemotherapy with temozolomide and anti - angiogenic therapy bevacizumab , have significantly improved the overall survival.

Article Details
  • Section
  • Research Articles
Download data is not yet available.
Cance & Huether Mc, Pathophyciology: the biologic basis for disease in adults and children, Mosby (4th ed) St Louis, 2002.
Lemone P, Burke K, «Παθολογική – Χειρουργική Νοσηλευτική», εκδόσεις Λαγός, 3η έκδοση Αθήνα 2004.
Louis D.N, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P, The 2007 WHO classification of tumours of the central nervous system,
Acta Neuropathol 2007;14(2):97-109.
Rousseau A, Mokhtari K, Duyckaerts C, The 2007 WHO classification of tumors of the central nervous system - what has changed? Current Opinion in Neurology 2008
Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY, Primary brain tumours in adults, Lancet 2003;361: 323-331.
Harrison T, Εσωτερική Παθολογία, εκδόσεις Παρισιάνου, 16η έκδοση, Αθήνα 2005.
Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.N
Engl J Med 2005;352(10):987-96.
Eom KY, Cho BJ, Choi EJ, Kim JH, Chie EK, Wu HG, Kim IH, Paek SH, Kim JS, Kim IA. The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and
Temozolomide on Malignant Glioma Cells in vitro and in vivo. Cancer Res Treat 2015 Jun 4.
Zhang W, Qiu XG, Chen BS, Li SW, Cui Y, Ren H, Jiang T. Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core
pathway aberrations. Chin Med J (Engl) 2009;122(11): 1250-4.
Carlson JA , Reddy Κ , Gaspar LE , Ney D , Kavanagh BD , Damek D, et al. Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials. J Neurooncol 2015;123(2):251-7.
Kostaras X, Cusano F, Kline GA, Roa W, Easaw J. Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline, Current Oncology 2014;
Hainaut P. The tumor suppressor protein P53: a receptor to genotoxic stress that controls cell growth andsurvival. Current Opinion Oncology 1995; 7:76–82.
Tishler Rb, Calderwood SK, Coleman CN, Price BD. Increases in sequence-specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging
agents. CancerRes 1993; 53:2212–2216.
Donehower La, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, et al. Ice deficient for p53 are developmentally normal, but susceptible to spontaneous tumors 1992; 356:215–221.
Porth C, Pathophysiology: Concepts of altered health states (6thed), Philadelphia: Lippincott, 2002.
Bondy M, Scheurer M, Malmer B, BarnholtzSloan J, Davis F, Il’yasova D et al. Brain Tumor Epidemiology: Consensus from the Brain Tumor Epidemiology Consortium
(BTEC), Cancer 2008; 113(7 Suppl): 1953– 1968.
Vida S, Richardson L, Cardis E, Krewski D, McBride M, Parent M-E, et al. Brain tumours and cigarette smoking: analysis of the INTERPHONE Canada case–control
study. Environ Health 2014; 13: 55.
Rehm J, Baliunas D, Guilherme L, Borges G, Graham K, lrving H, et al. The relation between different dimensios of alcohol consumption and burden of disease- an
overview. Addiction 2010;105(5):817-43.
Φερτάκης Α, Παθολογική Φυσιολογία, εκδόσεις Πασχαλίδης,2009.
Stranjalis G, Kalamatianos T, Stavrinou L, Mathios D, Koutsarnakis C, Tzavara C , et al. The Evangelismos hospital central nervous system tumor registry: Analysis of 1414
cases (1998-2009). Surg Neurol Int 2013; 4:23.
Friedlein K, Bozhkov Y, Hore N, Merkel A, Sommer B, Brandner S, et al. A new functional classification system (FGA/B) with prognostic value for glioma patients.
Sci Rep. 2015 Jul 21;5:12373.
Gao J, Wang Z, Liu H, Wang L, Huang G,Liposomeencapsulated of temozolomide for the treatment of gliomatumor: preparation, characterization and evaluation.Drug Discov
Ther 2015;9(3):205-12.
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma.J Clin Oncol 2009; 27(28):4733-40.
Most read articles by the same author(s)